SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Northwest Biotherapeutics Inc.
NWBO 0.239+2.8%2:36 PM EDT

 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Area51 who wrote (752)12/29/2020 4:40:45 PM
From: Gary Mohilner   of 759
 
I still believe that they'll issue the delinquent quarterly by the end of the year unless it's actually discussions with the SEC that are causing the delay. People seem to believe this could be the case, if it is, I don't think it harms us in terms of moving up to a different exchange once we meet the required share price and/or market cap.

I suspect that what people are saying about having a report of the trial accepted by either NEJM or Lancet prior to TLD being announced is very possible. I'm not certain they'll hold until actual publication, but once accepted the article can be considered peer reviewed as I understand it, that would permit the company to talk about it beyond what's said in the TLD statement itself. I don't know how close we are to this occurring, but I don't think it will be too much longer.

I wish something were done that would get us an invite to the J.P. Morgan Healthcare Conference, which I believe starts on January 11th. I think an invitation could be given just days before the virtual conference if the company does release TLD before then. I believe much of the Institutional investor community will look in on what's presented there.

Have a Happy and Safe New Year's,

Gary
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext